The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) hit a new 52-week low and has $3.87 target or 5.00% below today’s $4.07 share price. The 5 months bearish chart indicates high risk for the $548.53 million company. The 1-year low was reported on Nov, 3 by Barchart.com. If the $3.87 price target is reached, the company will be worth $27.43M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 4.23M shares traded hands or 211.03% up from the average. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has declined 23.74% since April 1, 2016 and is downtrending. It has underperformed by 24.95% the S&P500.
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Ratings Coverage
Out of 9 analysts covering Achillion Pharma (NASDAQ:ACHN), 6 rate it a “Buy”, 1 “Sell”, while 2 “Hold”. This means 67% are positive. Achillion Pharma has been the topic of 14 analyst reports since August 13, 2015 according to StockzIntelligence Inc. The firm has “Outperform” rating by Robert W. Baird given on Friday, February 26. The firm has “Sell” rating by Chardan Capital Markets given on Thursday, July 14. Wedbush initiated the shares of ACHN in a report on Friday, September 23 with “Outperform” rating. As per Thursday, August 13, the company rating was maintained by Maxim Group. Leerink Swann maintained Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) on Wednesday, May 4 with “Market Perform” rating. The rating was maintained by Maxim Group on Thursday, February 25 with “Buy”. The rating was maintained by Chardan Capital Markets on Friday, September 23 with “Sell”. On Thursday, September 15 the stock rating was initiated by FBR Capital with “Outperform”. Jefferies initiated Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) rating on Wednesday, September 9. Jefferies has “Hold” rating and $8 price target. As per Tuesday, September 8, the company rating was upgraded by UBS.
According to Zacks Investment Research, “ACHILLION PHARMACEUTICALS, INC. is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The company’s proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease — HIV, hepatitis and resistant bacterial infections. Achillion sees significant competitive advantages in developing anti-infective drugs compared to developing drugs in other therapeutic areas. The emergence of drug resistance seen with current antiviral and antibacterial therapies creates a continuing need for new drugs, providing a large and growing potential business opportunity. In addition, development cycle times tend to be somewhat shorter in infectious disease than other therapeutic areas, and early drug development results tend to be more predictive of longer term results.”
Insitutional Activity: The institutional sentiment increased to 1 in Q2 2016. Its up 0.08, from 0.92 in 2016Q1. The ratio improved, as 21 funds sold all Achillion Pharmaceuticals, Inc. shares owned while 39 reduced positions. 12 funds bought stakes while 48 increased positions. They now own 107.31 million shares or 4.98% less from 112.94 million shares in 2016Q1.
California Public Employees Retirement Sys accumulated 0% or 182,600 shares. Td Asset Mngmt reported 144,608 shares or 0% of all its holdings. Orbimed Advsr Ltd Liability Corp last reported 0.95% of its portfolio in the stock. The Connecticut-based Trexquant Inv Limited Partnership has invested 0.02% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Gp Incorporated holds 67,453 shares or 0% of its portfolio. Columbus Circle Invsts, a Connecticut-based fund reported 110,174 shares. Pacad Limited has 2,300 shares for 0% of their US portfolio. Product Prtn Limited Liability accumulated 285,600 shares or 0.18% of the stock. Invesco last reported 0% of its portfolio in the stock. Highbridge Mngmt Ltd holds 28,872 shares or 0% of its portfolio. Blackrock Group Inc Ltd last reported 0% of its portfolio in the stock. Rhenman And Prns Asset Ab holds 0.37% or 266,000 shares in its portfolio. Ubs Asset Mgmt Americas Inc holds 0% or 66,998 shares in its portfolio. Teacher Retirement System Of Texas has 15,173 shares for 0% of their US portfolio. Millennium Mgmt Ltd Liability Corp reported 3.23 million shares or 0.06% of all its holdings.
ACHN Company Profile
Achillion Pharmaceuticals, Inc., incorporated on August 5, 1998, is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Firm is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system. The complement system is part of the body’s immune system. The Firm has initiated a first-in-human Phase I clinical trial for its first complement factor D inhibitor, ACH-4471, to assess safety, tolerability, pharmacokinetics, or PK, and pharmacodynamics, or PD.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.